Sector News

Stryker expands ambulance services with Physio-Control buy

February 17, 2016
Life sciences

Medical device maker Stryker Corp said it would buy Physio-Control International Inc for $1.28 billion in cash to expand its emergency medical services business and raised its full-year earnings forecast for the second time this month.

Stryker has been on the look out for deals. The company earlier this month inked a deal with medical supplies maker Sage Products LLC for $2.78 billion and said it had the capacity and the capital for more deals.

The company would be a bit more active in terms of deals this year, Stryker Chief Executive Kevin Lobo said on a call with analysts on Tuesday.

Redmond, Washington-based Physio-Control, a unit of Bain Capital Private Equity, makes devices such as defibrillators for emergency treatment of cardiac arrests.

Sudden cardiac arrest is one of the leading causes of death worldwide. The condition accounts for over 300,000 deaths in the United States annually, Stryker said.

Physio-Control was a unit of heart device maker Medtronic Plc since 1998, but was spun-off in 2006. Five years later, Bain Capital acquired Physio-Control, which had fiscal 2015 sales of $503 million.

Stryker raised its full-year adjusted earnings forecast to $5.57-$5.77 per share from the $5.55-$5.75 range it estimated when it bought Sage Products.

The company also said it expects the acquisition of Physio-Control and Sage Products to add about 15-18 cents per share to earnings in 2017.

The Physio-Control deal would also boost Stryker’s emergency medical systems business in European countries including North Ireland, Sweden and Denmark.

Emergency medical services, also known as ambulance services, provides out-of-hospital acute medical care and medical transport to patients who are unable to reach the hospitals due to sudden illness and injuries.

Citi and Jefferies LLC advised Stryker for the Physio-Control deal while Skadden, Arps, Slate, Meagher & Flom LLP was its legal counsel. Kirkland & Ellis LLP was the legal counsel to Bain Capital.

Stryker’s shares were up 0.52 percent at $97.79 on the New York Stock Exchange on Tuesday.

By Rosmi Shaji

Source: Reuters

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach